Randomised Trial of Proton vs. Carbon Ion Radiation Therapy in Patients With Low and Inter-mediate Grade Chondrosarcoma of the Skull ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2010-2022

ABSTRACT

The study is a prospective randomised clinical phase III trial. Proton therapy is the gold standard in the treatment of low and intermediate grad chondrosarcomas of the skull base. However, high-LET beams such as carbon ions theoretically offer biologic advantages by enhanced biologic effectiveness in slow-growing tumors. Up until now it was impossible to compare two different particle therapies, i.e. proton and carbon ion therapy directly with each other. The aim of this study is to find out, whether the biological advantages of carbon ion therapy mentioned above can also be clinically confirmed. Detailed Description The study is a prospective randomised clinical phase III trial. The trial will be carried out at Heidelberger Ionenstrahl-Therapie (HIT) centre as monocentric trial.Proton therapy is the gold standard in the treatment of low and intermediate grad chondrosarcomas of the skull base. However, high-LET beams such as carbon ions theoretically offer biologic advantages by enhanced biologic effectiveness in slow-growing tumors. Up until now it was impossible to compare two different particle therapies, i.e. proton and carbon ion therapy directly with each other. The aim of this study is to find out, whether the biological advantages of carbon ion therapy mentioned above can also be clinically confirmed.Patients with skull base chondrosarcomas will be randomised to either proton or carbon ion radiation therapy. As a standard, patients will undergo non-invasive, rigid immobilization and target volume definition will be carried out based on CT and MRI data. The biologically isoeffective target dose to the PTV in carbon ion treatment will be 60 Gy E ± 5% and 70 Gy E ± 5% (standard dose) in proton therapy respectively. The 5 year local-progression free survival (LPFS) rate will be analysed as primary end point. Overall survival, progression free and metastasis free survival, patterns of recurrence, local control rate and morbidity are the secondary end points. Plan quality is also a matter of interest. More... »

URL

https://clinicaltrials.gov/show/NCT01182753

Related SciGraph Publications

  • 1999-06. Proton therapy for tumors of the skull base in STRAHLENTHERAPIE UND ONKOLOGIE
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "description": "The study is a prospective randomised clinical phase III trial. Proton therapy is the gold standard in the treatment of low and intermediate grad chondrosarcomas of the skull base. However, high-LET beams such as carbon ions theoretically offer biologic advantages by enhanced biologic effectiveness in slow-growing tumors. Up until now it was impossible to compare two different particle therapies, i.e. proton and carbon ion therapy directly with each other. The aim of this study is to find out, whether the biological advantages of carbon ion therapy mentioned above can also be clinically confirmed.\n\nDetailed Description\nThe study is a prospective randomised clinical phase III trial. The trial will be carried out at Heidelberger Ionenstrahl-Therapie (HIT) centre as monocentric trial.Proton therapy is the gold standard in the treatment of low and intermediate grad chondrosarcomas of the skull base. However, high-LET beams such as carbon ions theoretically offer biologic advantages by enhanced biologic effectiveness in slow-growing tumors. Up until now it was impossible to compare two different particle therapies, i.e. proton and carbon ion therapy directly with each other. The aim of this study is to find out, whether the biological advantages of carbon ion therapy mentioned above can also be clinically confirmed.Patients with skull base chondrosarcomas will be randomised to either proton or carbon ion radiation therapy. As a standard, patients will undergo non-invasive, rigid immobilization and target volume definition will be carried out based on CT and MRI data. The biologically isoeffective target dose to the PTV in carbon ion treatment will be 60 Gy E \u00b1 5% and 70 Gy E \u00b1 5% (standard dose) in proton therapy respectively. The 5 year local-progression free survival (LPFS) rate will be analysed as primary end point. Overall survival, progression free and metastasis free survival, patterns of recurrence, local control rate and morbidity are the secondary end points. Plan quality is also a matter of interest.", 
        "endDate": "2022-08", 
        "id": "sg:clinicaltrial.NCT01182753", 
        "keywords": [
          "clinical phase III trials", 
          "phase III trials", 
          "carbon ion radiation therapy", 
          "skull base", 
          "III trials", 
          "ion radiation therapy", 
          "radiation therapy", 
          "local progression-free survival rates", 
          "clinical phase III studies", 
          "end point", 
          "carbon ion therapy", 
          "trial of protons", 
          "Secondary end points", 
          "primary end point", 
          "free survival rate", 
          "local control rate", 
          "phase III study", 
          "patterns of recurrence", 
          "gold standard", 
          "proton therapy", 
          "biologic advantages", 
          "target volume definition", 
          "skull base chondrosarcoma", 
          "biologic effectiveness", 
          "monocentric trial", 
          "free survival", 
          "III study", 
          "overall survival", 
          "control rate", 
          "grade chondrosarcoma", 
          "target dose", 
          "ion therapy", 
          "survival rate", 
          "therapy", 
          "Gy E", 
          "chondrosarcoma", 
          "patients", 
          "particle therapy", 
          "volume definition", 
          "carbon ion treatment", 
          "trials", 
          "rigid immobilization", 
          "biological advantages", 
          "plan quality", 
          "tumors", 
          "treatment", 
          "MRI data", 
          "survival", 
          "morbidity", 
          "recurrence", 
          "aim", 
          "study", 
          "dose", 
          "progression", 
          "CT", 
          "PTV", 
          "rate", 
          "high-LET beams", 
          "standards", 
          "matter of interest", 
          "center", 
          "effectiveness", 
          "ion treatment", 
          "carbon ions", 
          "patterns", 
          "data", 
          "low", 
          "quality", 
          "base", 
          "point", 
          "detailed description", 
          "advantages", 
          "definition", 
          "immobilization", 
          "interest", 
          "matter", 
          "description", 
          "protons", 
          "ions", 
          "beam"
        ], 
        "name": "Randomised Trial of Proton vs. Carbon Ion Radiation Therapy in Patients With Low and Inter-mediate Grade Chondrosarcoma of the Skull Base, Clinical Phase III Study", 
        "sameAs": [
          "https://app.dimensions.ai/details/clinical_trial/NCT01182753"
        ], 
        "sdDataset": "clinical_trials", 
        "sdDatePublished": "2022-09-02T16:19", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/clinical_trial/clinical_trial_1.jsonl", 
        "startDate": "2010-08", 
        "subjectOf": [
          {
            "id": "sg:pub.10.1007/bf03038890", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032828853", 
              "https://doi.org/10.1007/bf03038890"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "type": "MedicalStudy", 
        "url": "https://clinicaltrials.gov/show/NCT01182753"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01182753'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01182753'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01182753'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01182753'


     

    This table displays all metadata directly associated to this object as RDF triples.

    107 TRIPLES      15 PREDICATES      97 URIs      89 LITERALS      1 BLANK NODES

    Subject Predicate Object
    1 sg:clinicaltrial.NCT01182753 schema:about anzsrc-for:11
    2 anzsrc-for:1103
    3 anzsrc-for:1112
    4 schema:description The study is a prospective randomised clinical phase III trial. Proton therapy is the gold standard in the treatment of low and intermediate grad chondrosarcomas of the skull base. However, high-LET beams such as carbon ions theoretically offer biologic advantages by enhanced biologic effectiveness in slow-growing tumors. Up until now it was impossible to compare two different particle therapies, i.e. proton and carbon ion therapy directly with each other. The aim of this study is to find out, whether the biological advantages of carbon ion therapy mentioned above can also be clinically confirmed. Detailed Description The study is a prospective randomised clinical phase III trial. The trial will be carried out at Heidelberger Ionenstrahl-Therapie (HIT) centre as monocentric trial.Proton therapy is the gold standard in the treatment of low and intermediate grad chondrosarcomas of the skull base. However, high-LET beams such as carbon ions theoretically offer biologic advantages by enhanced biologic effectiveness in slow-growing tumors. Up until now it was impossible to compare two different particle therapies, i.e. proton and carbon ion therapy directly with each other. The aim of this study is to find out, whether the biological advantages of carbon ion therapy mentioned above can also be clinically confirmed.Patients with skull base chondrosarcomas will be randomised to either proton or carbon ion radiation therapy. As a standard, patients will undergo non-invasive, rigid immobilization and target volume definition will be carried out based on CT and MRI data. The biologically isoeffective target dose to the PTV in carbon ion treatment will be 60 Gy E ± 5% and 70 Gy E ± 5% (standard dose) in proton therapy respectively. The 5 year local-progression free survival (LPFS) rate will be analysed as primary end point. Overall survival, progression free and metastasis free survival, patterns of recurrence, local control rate and morbidity are the secondary end points. Plan quality is also a matter of interest.
    5 schema:endDate 2022-08
    6 schema:keywords CT
    7 Gy E
    8 III study
    9 III trials
    10 MRI data
    11 PTV
    12 Secondary end points
    13 advantages
    14 aim
    15 base
    16 beam
    17 biologic advantages
    18 biologic effectiveness
    19 biological advantages
    20 carbon ion radiation therapy
    21 carbon ion therapy
    22 carbon ion treatment
    23 carbon ions
    24 center
    25 chondrosarcoma
    26 clinical phase III studies
    27 clinical phase III trials
    28 control rate
    29 data
    30 definition
    31 description
    32 detailed description
    33 dose
    34 effectiveness
    35 end point
    36 free survival
    37 free survival rate
    38 gold standard
    39 grade chondrosarcoma
    40 high-LET beams
    41 immobilization
    42 interest
    43 ion radiation therapy
    44 ion therapy
    45 ion treatment
    46 ions
    47 local control rate
    48 local progression-free survival rates
    49 low
    50 matter
    51 matter of interest
    52 monocentric trial
    53 morbidity
    54 overall survival
    55 particle therapy
    56 patients
    57 patterns
    58 patterns of recurrence
    59 phase III study
    60 phase III trials
    61 plan quality
    62 point
    63 primary end point
    64 progression
    65 proton therapy
    66 protons
    67 quality
    68 radiation therapy
    69 rate
    70 recurrence
    71 rigid immobilization
    72 skull base
    73 skull base chondrosarcoma
    74 standards
    75 study
    76 survival
    77 survival rate
    78 target dose
    79 target volume definition
    80 therapy
    81 treatment
    82 trial of protons
    83 trials
    84 tumors
    85 volume definition
    86 schema:name Randomised Trial of Proton vs. Carbon Ion Radiation Therapy in Patients With Low and Inter-mediate Grade Chondrosarcoma of the Skull Base, Clinical Phase III Study
    87 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01182753
    88 schema:sdDatePublished 2022-09-02T16:19
    89 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    90 schema:sdPublisher N9b3c7d86eecb4e81b3d6876b0bf1afbe
    91 schema:startDate 2010-08
    92 schema:subjectOf sg:pub.10.1007/bf03038890
    93 schema:url https://clinicaltrials.gov/show/NCT01182753
    94 sgo:license sg:explorer/license/
    95 sgo:sdDataset clinical_trials
    96 rdf:type schema:MedicalStudy
    97 N9b3c7d86eecb4e81b3d6876b0bf1afbe schema:name Springer Nature - SN SciGraph project
    98 rdf:type schema:Organization
    99 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    100 rdf:type schema:DefinedTerm
    101 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    102 rdf:type schema:DefinedTerm
    103 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    104 rdf:type schema:DefinedTerm
    105 sg:pub.10.1007/bf03038890 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032828853
    106 https://doi.org/10.1007/bf03038890
    107 rdf:type schema:CreativeWork
     




    Preview window. Press ESC to close (or click here)


    ...